SCHEMBL4055855

SCHEMBL4055855

NCCCCCCN1c2ccccc2N(c2ccccc2F)S1(=O)=O

nearest known ligand 0.70

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 20/20 0.70
SLC6A4 P31645 7/20 0.70
SLC6A3 Q01959 11/20 0.67
KCNH2 Q12809 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059908 1.00 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4065517 0.99 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4057467 0.94 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4061774 0.88 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4063690 0.87 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL3612440 0.87 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL4054682 0.87 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL14161185 0.87 SLC6A2 (0.59) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4055605 0.86 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4064689 0.84 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP claimed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US claimed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO claimed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885SLC6A4 1/4885SLC6A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.